# US 2024/0197930 A1 · Pet tracer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197930 A1
- Document ID: US20240197930A1
- Status: Published application
- Kind: A1
- Application number: 18/529,406
- Filed: 2023-12-05
- Published: 2024-06-20
- Earliest claimed: 2022-12-14
- Assignees: Antaros Tracer AB
- Applicants: Antaros Tracer AB
- Inventors: Olof ERIKSSON
- Web page: https://patentgrep.com/patent/US20240197930A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides conjugated binding molecules comprising platelet-derived growth factor receptor beta (PDGF-Rβ) binding polypeptides conjugated to radionuclides chelated by a Restrained Complexing Agent (RESCA) chelator, wherein Aluminum-Fluorine-18 is the preferred radionuclide. The PDGF-Rβ binding polypeptide comprises a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of an amino acid sequence as defined herein, wherein the PDGF-Rβ-binding polypeptide binds to PDGF-Rβ such that the KD value of the interaction is at most 1×10−6 M. Also provided are methods and uses of said conjugated binding molecule in imaging and diagnosis of PDGF-Rβ-related conditions, such as fibrosis.

## Claims

### Claim 1

A conjugated binding molecule comprising:
i) at least one binding polypeptide, the binding polypeptide being a platelet derived growth factor receptor beta (PDGF-Rβ) binding polypeptide; and
ii) at least one agent, the at least one agent being indirectly joined to the binding polypeptide via a linker in the form of a chelator, wherein the at least one agent comprises or consists of a radionuclide and wherein the chelator is Restrained Complexing Agent (RESCA).

### Claim 2 (depends on 1)

The conjugated binding molecule according to claim 1, wherein the radionuclide is Fluorine-18 conjugated to Aluminum in the form of Aluminum-Fluorine-18 (Al18F).

### Claim 3 (depends on 1)

The conjugated binding molecule according to claim 1, wherein the at least one PDGF-Rβ binding polypeptide comprises a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of the amino acid sequence selected from
i) EX2X3X4AAX7EID X11LPNLX16X17X18QW NAFIX25X26LX28X29,
wherein, independently of each other,
X2 is selected from L, R and I;
X3 is selected from R, I, L, V, K, Q, S, H, and A;
X4 is selected from A, R, N, D, Q, E, H, K, M, S, T, W, F and V;
X7 is selected from A, R, D, Q, E, G, K and S;
X11 is selected from A, R, N, D, E, G, K, S, T and Q;
X16 is selected from N and T;
X17 is selected from R and K;
X13 is selected from A, R, N, D, C, Q, E, G, L, K, M, S, T, W and V;
X25 is selected from K, R, Q, H, S, G and A;
X26 is selected from S and K;
X28 is selected from V, R, I, L and A;
X29 is selected from D and K; and
ii) an amino acid sequence which has at least 89% identity to the sequence defined in i), and wherein
the PDGF-Rβ-binding polypeptide binds to PDGF-Rβ such that the KD value of the interaction is at most 1×10−6 M.

### Claim 4 (depends on 3)

The conjugated binding molecule according to claim 3, wherein said PDGF-Rβ-binding motif forms part of a three-helix bundle protein domain, and wherein in which said PDGF-Rβ-binding motif essentially forms part of two alpha helices with an interconnecting loop, within said three-helix bundle protein domain.

### Claim 5 (depends on 3)

The conjugated binding molecule according to claim 3, wherein at least one PDGF-Rβ binding polypeptide comprises an amino acid sequence selected from:
VDNKFNK-[PBM]-DPSQSANLLAEAKKLNDAQAPK; and
AENKFNK-[PBM]-DPSQSANLLAEAKKLNDAQAPKC.

### Claim 6 (depends on 3)

The conjugated binding molecule according to claim 3, wherein at least one PDGF-Rβ binding polypeptide comprises an amino acid sequence selected from SEQ ID NO: 4-351

### Claim 7 (depends on 3)

The conjugated binding molecule according to claim 3, wherein at least one PDGF-Rβ binding polypeptide is a Z-molecule comprising the amino acid sequence:
(SEQ ID NO: 237)
AENKFNKELIEAAAEIDALPNLNRRQWNAFIKSLVDDPSQSANLLAEAK
KLNDAQAPKC.

### Claim 8 (depends on 7)

The conjugated binding molecule according to claim 7, wherein the binding polypeptide is the Z-molecule comprising the amino acid sequence SEQ ID NO: 237 and the radionuclide is Al18F, and wherein the conjugated binding molecule has the construct: Al18F-RESCA-Z.

### Claim 9 (depends on 1)

The conjugated binding molecule according to claim 1, wherein the chelator is joined to the binding polypeptide via a linker.

### Claim 10 (depends on 1)

A conjugated binding molecule according to claim 1, for use in Position Emission Tomography (PET) imaging.

### Claim 11 (depends on 1)

A conjugated binding molecule according to claim 1, for use in the assessment of fibrosis, fibrosis degree and/or active fibrogenesis.

### Claim 12 (depends on 1)

An in vivo method for detecting activated fibroblast cells and/or activated mesenchymal stromal cells in a subject by detecting expression of platelet derived growth factor receptor beta (PDGF-Rβ), the method comprising:
(i) administering one or more conjugated binding molecules of claim 1 to the subject; and
(ii) detecting that the one or more conjugated binding molecule has bound fibroblast cells and/or mesenchymal stromal cells, wherein the bound fibroblast cells and/or bound mesenchymal stromal cells are determined as being activated.
